Panacea Biotec Pharma Limited Mycophenolate Export Data — India (DGFT 2022–2026)

Name: Panacea Biotec Pharma Limited Mycophenolate Export Records India — #7 Exporter, 35 Shipments, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Mycophenolate

India Pharmaceutical Trade Intelligence

$334.4M167 Suppliers100 CountriesHS 30049099

ExportsIndia → UNITED STATES76.6%India → AUSTRALIA6.1%

ImportsGERMANY → India$999.6M ITALY → India$223.6M

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: EVERSANA LIFE

Panacea Biotec Pharma Limited — Mycophenolate Exporter #7 | $1.8M Trade Value | TransData Nexus | TransData Nexus

Panacea Biotec Pharma Limited — Mycophenolate Exporter Profile

Indian Pharmaceutical Exporter · #7 for Mycophenolate · $1.8M export value · DGFT Verified

Panacea Biotec Pharma Limited is the #7 Indian exporter of Mycophenolate with $1.8M in export value and 35 verified shipments. Panacea Biotec Pharma Limited holds a 0.5% market share in Mycophenolate exports across 9 countries. The company exports 13 pharmaceutical products worth $23.9M across 9 therapeutic categories.

Panacea Biotec Pharma Limited — Mycophenolate Export Profile: Buyers & Destinations

Panacea Biotec Pharma Limited Mycophenolate export treemap — buyers and destination countries | TransData Nexus

Where Does Panacea Biotec Pharma Limited Export Mycophenolate?

Country	Value	Shipments	Share
PHILIPPINES	$344.7K	7	45.4%
KAZAKHSTAN	$140.4K	4	18.5%
MYANMAR	$84.7K	3	11.2%
ECUADOR	$50.0K	1	6.6%
LEBANON	$50.0K	1

Who Are the Top Buyers of Mycophenolate from Panacea Biotec Pharma Limited?

Buyer	Country	Value	Orders
DEGA INTERNATIONAL PHARMA CORP,	PHILIPPINES	$194.7K	4
TOO ROGER PHARMA	KAZAKHSTAN	$163.9K	7
RIGHT BRIGHT INTERNATIONAL COMPAN	MYANMAR	$84.7K	3
M S DEGA INTERNATIONAL PHARMA CORP	PHILIPPINES	$50.0K	1
DEGA INTERNATIONAL PHARMA CORP RM	PHILIPPINES	$50.0K	1
BANCO BOLIVARIANO C.A.	ECUADOR	$50.0K	1
NUTRAVIT SAL (OFFSHORE)	LEBANON	$50.0K	1
DEGA INTERNATIONAL PHARMA CORP	PHILIPPINES	$50.0K	1
MARKSS HLC PVT LTD	SRI LANKA	$18.8K	1
AP SCOTT TRINIDAD LIMITED	TRINIDAD & TOBAGO	$11.0K	1

Panacea Biotec Pharma Limited supplies Mycophenolate to 16 buyers globally. The largest buyer is DEGA INTERNATIONAL PHARMA CORP, (PHILIPPINES), followed by TOO ROGER PHARMA (KAZAKHSTAN) and RIGHT BRIGHT INTERNATIONAL COMPAN (MYANMAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Mycophenolate Formulations Does Panacea Biotec Pharma Limited Export?

Product Description / Formulation	Value	Shipments
MYCEPT250 MG CAPSULES (EACH HARD GELATINCAPSULE CONTAINS MYCOPHENOLATE MOFETIL250 MG) (TOTAL 451500 CAPSULES INLCLUDIN	$62.9K	2
MYCEPT 500 EACH TABLET CONTAINS MYCOPHENOLATE MOFETIL 500 MG B/N.12423003 M/D.08/2023 E/D.07/2026.	$50.0K	1
MYCEPT 500 EACH TABLET CONTAINS MYCOPHENOLATE MOFETIL 500 MG B/N.12423003 M/D.08/2023 E/D.07/2026 B/N.12423004 M/D.09/	$50.0K	1
MYCOPHENOLATE SODIUM ENTERIC COATED TABLETS 360 MG (EACH ENTERIC COATED TABLET CONTAINS MYCOPHENOLATE ACID (AS SODIUM SA	$50.0K	1
BLEND FOR MYCOPHENOLATE MOFETIL B/N.800223001 & 800223002 M/D.10/2023 E/D.09/2025.	$50.0K	1
MYCEPT-500 TABLETS EACH TABLET CONTAINS: MYCOPHENOLATE MOFETIL 500MG) B/N.12424008 M/D.12/2024 E/D.11/2027.	$50.0K	1
MYCEPT 500 (EACH TABLET CONTAINS MYCOPHENOLATE MOFETIL 500 MG) B/N.12423006 & 12423007 M/D.02/2024 E/D.01/2027.	$50.0K	1
MYCEPT-500 TABLETS ( EACH TABLET CONTAINS: MYCOPHENOLATE MOFETIL 500MG) B/N.12424009 M/D.02/2025 E/D.01/2028.	$50.0K	1
MYCEPT 500 TABLETS EACH TABLET CONTAINSMYCOPHENOLATE MOFETIL 500 MG B N 12424011 12424012 M D 03 2025 E D 02 2028	$50.0K	1
MYCEPT 250 MG CAPSULES (EACH HARD GELATIN CAPSULE CONTAINS MYCOPHENOLATE MOFETIL250 MG) (TOTAL 681870 CAPSULES INCLUDIN	$48.6K	1

Panacea Biotec Pharma Limited exports 26 distinct Mycophenolate formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MYCEPT250 MG CAPSULES (EACH HARD GELATINCAPSULE CONTAINS MYC with 2 shipments worth $62.9K.

How Does Panacea Biotec Pharma Limited Compare to Nearest Mycophenolate Exporters?

Exporters ranked immediately above and below #7 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
6	CONCORD BIOTECH LIMITED	$6.0M	119	8	$50.0K
8	MYLAN LABORATORIES LIMITED	$1.8M	36	4	$50.0K
7	PANACEA BIOTEC PHARMA LIMITED ★	$1.8M	35	9	$50.0K
9	INTAS PHARMACEUTICALS LTD	$700.0K	14	6	$50.0K
12	ACME GENERICS PRIVATE LIMITED	$612.4K	14	1	$43.7K

Panacea Biotec Pharma Limited ranks #7 among 167 Indian Mycophenolate exporters. Average shipment value of $50.0K compared to the market average of $520.1K. The closest competitors by value are CONCORD BIOTECH LIMITED and MYLAN LABORATORIES LIMITED.

Which Indian Ports Ship Mycophenolate Exports?

Port	Shipments	% Share
SAHAR AIR	464	18.3%
NHAVA SHEVA SEA (INNSA1)	308	12.2%
SAHAR AIR CARGO ACC (INBOM4)	229	9.1%
JNPT/ NHAVA SHEVA SEA	135	5.3%
DELHI AIR	115	4.5%
AHEMDABAD AIR ACC (INAMD4)	108	4.3%
MUNDRA SEA	97	3.8%
BANGALORE ICD	97	3.8%

Geopolitical & Trade Policy Impact on Panacea Biotec Pharma Limited's Mycophenolate Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Panacea Biotec. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight charges and potential delays. These maritime disruptions are particularly concerning for time-sensitive pharmaceutical shipments, as extended transit times and congestion elevate the risk of cold-chain failures for vaccines and biologics. (pharmaceuticalcommerce.com)

In the United States, recent tariff implementations have introduced uncertainties for Indian exporters. While health products have been exempt from U.S. tariffs, there is growing concern that this exemption may not be permanent. The potential imposition of tariffs on pharmaceutical imports could impact Panacea Biotec's profitability, given the company's significant export volume to the U.S. market. (lemonde.fr)

Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to capture market share previously held by Chinese manufacturers. This shift presents an opportunity for Panacea Biotec to expand its footprint in the U.S. market, provided it can navigate the evolving regulatory and trade environment effectively.

In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. The recent GMP non-compliance issue at Panacea Biotec's Baddi facility underscores the importance of adhering to stringent EU regulations. Addressing these compliance challenges promptly is essential to maintain and grow the company's presence in European markets.

Panacea Biotec Pharma Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency (EMA) enforcing stringent quality standards. For Indian exporters, maintaining compliance with these standards is paramount to ensure uninterrupted market access.

Panacea Biotec's recent GMP non-compliance at its Baddi facility highlights the critical need for robust quality management systems. The company has committed to implementing comprehensive corrective and preventive actions and plans to request a re-inspection to reinstate its GMP certificates. (prysm.fi) Proactive measures in quality assurance will be vital for Panacea Biotec to rebuild trust with regulatory bodies and international clients.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Mycophenolate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Panacea Biotec Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 35 individual customs records matching Panacea Biotec Pharma Limited exporting Mycophenolate, covering 26 formulations to 10 countries via 16 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 100+ countries, 512+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Mycophenolate

Mycophenolate

Panacea Biotec Pharma Limited — Mycophenolate Exporter Profile

Panacea Biotec Pharma Limited — Mycophenolate Export Profile: Buyers & Destinations

Where Does Panacea Biotec Pharma Limited Export Mycophenolate?

Who Are the Top Buyers of Mycophenolate from Panacea Biotec Pharma Limited?

What Is India's Total Mycophenolate Export Value and How Much Does Panacea Biotec Pharma Limited Contribute?

What Is the Average Shipment Value for Panacea Biotec Pharma Limited's Mycophenolate Exports?

How Does Panacea Biotec Pharma Limited Compare to Other Indian Mycophenolate Exporters?

What Mycophenolate Formulations Does Panacea Biotec Pharma Limited Export?

How Does Panacea Biotec Pharma Limited Compare to Nearest Mycophenolate Exporters?

Which Indian Ports Ship Mycophenolate Exports?

What Other Immunosuppressants Products Does Panacea Biotec Pharma Limited Export?

Geopolitical & Trade Policy Impact on Panacea Biotec Pharma Limited's Mycophenolate Exports

Panacea Biotec Pharma Limited — Regulatory Compliance & Quality Standards

About Panacea Biotec Pharma Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Mycophenolate Export Data from Panacea Biotec Pharma Limited

Mycophenolate Stats

Company Overview

Top Products by Panacea Biotec Pharma Limited

Related Analysis

Need Detailed Export Data?

Data Source